Pharma Leader Series: Top 20 Ophthalmic Drug Manufacturers 2012-2022
Introducing a new report to show you prospects for leading eye drug producers
What does the future hold for top companies in the pharma ophthalmics industry? Visiongain's new report shows you their prospects to 2022. You find financial data, trends, opportunities and revenue predictions.
We analyse 29 leading companies for eye medicines, to help you see the future of that industry and market. Discover how sales of ocular drugs can increase.
Discover forecasts and discussions to help you stay ahead in knowledge
You find revenue forecasts to 2022 for nine companies, 20 top drugs and the industry, with growth rates and market shares. Also, you see qualitative analysis (inc. SWOT), business outlooks and research and development (R&D). You receive 45 tables and 74 charts.
Our investigation lets you assess the most lucrative areas of that industry, especially pharma companies at the forefront of treating eye disorders and diseases. We predict sales growth with many opportunities.
You can stay ahead in knowledge of the ophthalmic treatments market, benefiting your research and analyses. The following sections highlight what you find in our report.
See prospects for leading US manufacturers
Our report gives you profiles and analyses for top companies based in the US:
You assess strengths, weaknesses, opportunities and threats (SWOT factors). Also, you find linked organisations, including alliances and licensing. Discover what the future holds. You see approvals and strategy too, and mergers and acquisitions (M&A activity).
Next, our investigation assesses prominent companies in other regions - Europe and Japan.
What are the outlooks for leading European producers?
Our report shows you developments and prospects for leading European pharma manufacturers developing and producing medicines for optical disorders:
What are the prospects for companies based in Japan?
You see outlooks for top Japanese companies developing and producing ocular drugs. Assess product portfolios, other activities and revenue predictions to 2022:
Who are the leading emerging companies worldwide?
Our study also covers 20 other companies following after the world leaders. You discover activities of organisations including the following:
You also find revenue predictions for the overall industry segment
Our report forecasts sales of ocular drugs by overall world market and product category. You see individual forecasted revenues and growth rates to 2022 for five world-level submarkets (therapeutic classes):
This decade there will be much progress, with novel drug launches. Pharma corporations and specialty healthcare operations will develop and prosper, our analysis shows.
Nine ways Pharma Leader Series: Top 20 Ophthalmic Drug Manufacturers 2012-2022 benefits you
To sum up, then, our investigation gives you the following knowledge:
With our report you are less likely to fall behind in knowledge. You see where prospects are lucrative and revenue growth is likely.
Discover how our work could benefit your research and analyses, saving you time too.
You see prospects for top eye drug producers by ordering now
Visiongain's new study is for everyone needing analysis of the industry and market for ophthalmic medicines. You find data, trends and predictions. Please order our report now.
What does the future hold for top companies in the pharma ophthalmics industry? Visiongain's new report shows you their prospects to 2022. You find financial data, trends, opportunities and revenue predictions.
We analyse 29 leading companies for eye medicines, to help you see the future of that industry and market. Discover how sales of ocular drugs can increase.
Discover forecasts and discussions to help you stay ahead in knowledge
You find revenue forecasts to 2022 for nine companies, 20 top drugs and the industry, with growth rates and market shares. Also, you see qualitative analysis (inc. SWOT), business outlooks and research and development (R&D). You receive 45 tables and 74 charts.
Our investigation lets you assess the most lucrative areas of that industry, especially pharma companies at the forefront of treating eye disorders and diseases. We predict sales growth with many opportunities.
You can stay ahead in knowledge of the ophthalmic treatments market, benefiting your research and analyses. The following sections highlight what you find in our report.
See prospects for leading US manufacturers
Our report gives you profiles and analyses for top companies based in the US:
- Allergan
- Pfizer
- Bausch + Lomb
- Merck & Co.
- Regeneron.
You assess strengths, weaknesses, opportunities and threats (SWOT factors). Also, you find linked organisations, including alliances and licensing. Discover what the future holds. You see approvals and strategy too, and mergers and acquisitions (M&A activity).
Next, our investigation assesses prominent companies in other regions - Europe and Japan.
What are the outlooks for leading European producers?
Our report shows you developments and prospects for leading European pharma manufacturers developing and producing medicines for optical disorders:
- Novartis
- Roche (Genentech).
What are the prospects for companies based in Japan?
You see outlooks for top Japanese companies developing and producing ocular drugs. Assess product portfolios, other activities and revenue predictions to 2022:
- Santen
- Senju.
Who are the leading emerging companies worldwide?
Our study also covers 20 other companies following after the world leaders. You discover activities of organisations including the following:
- BioDiem
- CoMentis
- Alimera Sciences
- ISTA Pharmaceuticals
- Shire
- Lpath
- Ophthotech Corporation
- OPKO Health
- Othera Pharmaceuticals.
You also find revenue predictions for the overall industry segment
Our report forecasts sales of ocular drugs by overall world market and product category. You see individual forecasted revenues and growth rates to 2022 for five world-level submarkets (therapeutic classes):
- Glaucoma
- Retinal disorders
- Dry eye
- Ophthalmic allergy, inflammation and infection
- Other agents.
This decade there will be much progress, with novel drug launches. Pharma corporations and specialty healthcare operations will develop and prosper, our analysis shows.
Nine ways Pharma Leader Series: Top 20 Ophthalmic Drug Manufacturers 2012-2022 benefits you
To sum up, then, our investigation gives you the following knowledge:
- Profiles of 29 leading companies - discover product ranges, recent results, strategies and competition
- Outlooks for companies in eye medicine - assess top players worldwide, seeing opportunities, business data, challenges and commercial outlooks
- Forecasted ophthalmic drug revenues to 2022 for the 9 top companies - find predicted financial results for those medicines
- Predicted revenues of 20 leading brands to 2022 - see potentials of top products
- Potential revenues to 2022 for the overall world ophthalmic drug market and 5 product categories (therapeutic classes) - find the industry's sales outlook
- Review of R&D pipelines - investigate developmental trends and progress
- Investigation of competition and opportunities influencing sales
- Discussion of what stimulates and restrains companies and the market
- Prospects for established firms and those seeking to enter the sector.
With our report you are less likely to fall behind in knowledge. You see where prospects are lucrative and revenue growth is likely.
Discover how our work could benefit your research and analyses, saving you time too.
You see prospects for top eye drug producers by ordering now
Visiongain's new study is for everyone needing analysis of the industry and market for ophthalmic medicines. You find data, trends and predictions. Please order our report now.
1. EXECUTIVE SUMMARY
1.1 Leading Ophthalmic Drug Manufacturers: Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report
1.4.1 Drugs Considered for this Report
2. AN INTRODUCTION TO THE OPHTHALMIC DRUGS MARKET
2.1 The Ophthalmic Drug Market
2.1.1 The Ophthalmic Drugs Market in 2011
2.2 Ophthalmic Disorders
2.2.1 Glaucoma
2.2.1.1 Glaucoma Risk Factors
2.2.1.2 Diagnosis and Prevalence of Glaucoma
2.2.1.3 Treatment of Glaucoma
2.2.1.4 First-Line and Second-Line Treatment of Choice
2.2.1.5 Laser Treatment and Surgery (Trabeculectomy)
2.2.2 Age-Related Macular Degeneration (AMD)
2.2.2.1 AMD Risk Factors, Prevalence and Diagnosis
2.2.2.2 Treatment of AMD
2.2.3 Diabetic Retinopathy
2.2.3.1 Diagnosis and Prevalence of Diabetic Retinopathy
2.2.3.2 Laser and Surgical Treatments for Diabetic Retinopathy
2.2.3.3 Pharmaceutical Treatments
2.2.4 Ophthalmic Allergies: Allergic Conjunctivitis is the Most-Common Eye Allergy
2.2.4.1 Ophthalmic Allergy Treatments
2.2.5 Ophthalmic Inflammatory Disorders
2.2.5.1 Ophthalmic Inflammatory Drugs
2.2.6 Ophthalmic Infections
2.2.6.1 Treatment of Eye Infections
2.2.7 Dry Eye Syndrome
2.2.7.1 Causes and Prevalence of Dry Eye Syndrome
2.2.7.2 Treatments for Dry Eye Syndrome
2.3 The Ophthalmic Drugs Market: Overall Revenue Forecast 2012-2022
2.3.1 Market Drivers 2012-2022
2.3.2 Market Restraints 2012-2022
2.4 Leading Ophthalmic Drug Manufacturers in 2011
2.4.1 Company Comparison
2.4.2 Future of the Ophthalmic Drugs Industry
3. THE LEADING US OPHTHALMIC DRUG MANUFACTURERS 2012-2022
3.1 Allergan
3.1.1 Ophthalmic Product Portfolio
3.1.2 Allergan's Leading Product Forecast
3.1.2.1 Restasis - Allergan's Prescription Drug for Dry Eye
3.1.2.1.1 Restasis Revenue Forecast, 2012-2022
3.1.2.2 Lumigan Franchise
3.1.2.2.1 Lumigan Franchise Revenue Forecast, 2012-2022
3.1.2.3 Allergan's Refresh Brand, including Celluvisc, a Leading Brand in the Dry Eye Market
3.1.2.3.1 Refresh Brand including Celluvisc: Revenue Forecast, 2012-2022
3.1.2.4 Alphagan
3.1.2.4 1 Alphagan Revenue Forecast, 2012-2022
3.1.2.5 Combigan
3.1.2.5.1 Combigan Revenue Forecast, 2012-2022
3.1.2.6 Acular
3.1.2.6.1 Acular Revenue Forecast, 2012-2022
3.1.2.7 Allergan's Ozurdex, First Drug Therapy for Macular Oedema
3.1.3 Allergan's Ophthalmic Pipeline
3.1.3.1 Novadur/Sustained-Release Brimonidine (Allergan)
3.1.3.2 AGN-745/SIRNA-027 (Allergan/Merck & Co.)
3.1.3.3 DARPin/MP0112 (Allergan)
3.1.3.4 Prolacria (Inspire/Allergan/Santen)
3.1.4 Allergan's Other Specialty Areas
3.1.5 Allergan Manufacturing Capabilities
3.1.6 Allergan Ophthalmic Segment: SWOT Analysis
3.1.7 Allergan's Revenues
3.1.7.1 Ophthalmic Revenue Forecast, 2012-2022
3.2 Pfizer
3.2.1 Ophthalmic Product Portfolio
3.2.1.1 Macugen (pegaptanib)
3.2.1.2 Xalatan (latanoprost)
3.2.1.3 Xalacom (latanoprost/timolol)
3.2.1.4 Xalabrands (Xalatan/Xalacom) Revenue Forecast, 2012-2022
3.2.2 Ophthalmic Revenue, 2011
3.2.3 R&D Pipeline
3.2.3.1 Pipeline, 2007-2011
3.2.3.2 iSONEP
3.2.3.3 Tofacitinib (CP-690550)
3.2.3.4 RN6G (PF-04382923)
3.2.3.5 AtuRNAi (PF-04523655)
3.2.4 Pfizer Ophthalmics: SWOT Analysis
3.2.5 Ophthalmic Revenue Forecast, 2012-2022
3.3 Bausch + Lomb
3.3.1 A Long History in Ophthalmics
3.3.2 Key Eye Care Business Segments
3.3.3 Vision Care
3.3.4 Surgical
3.3.5 Pharmaceuticals
3.3.5.1 Lotemax
3.3.5.2 Lotemax Revenue Forecast, 2012-2022
3.3.6 Ophthalmic Revenue, 2011
3.3.7 Pipeline Products
3.3.8 Recent Mergers and Acquisitions
3.3.9 Bausch + Lomb Ophthalmics: SWOT Analysis
3.3.10 Ophthalmic Revenue Forecast, 2012-2022
3.4 Merck & Co.
3.4.1 Ophthalmic Product Portfolio
3.4.1.1 Trusopt
3.4.1.2 Cosopt
3.4.1.3 Trusopt Revenue Forecast, 2012-2022
3.4.1.4 Cosopt Revenue Forecast, 2012-2022
3.4.2 Ophthalmic Revenue, 2011
3.4.3 FDA Approves Zioptan (tafluprost)
3.4.4 Recent Merger and Acquisition Deals
3.4.5 Pipeline
3.4.5.1 Prolacria (Inspire/Allergan/Santen)
3.4.6 Merck Ophthalmics: SWOT Analysis
3.4.7 Ophthalmic Revenue Forecast, 2012-2022
3.5 Regeneron
3.5.1 Ophthalmic Product Portfolio
3.5.1.1 Eylea (Regeneron/Bayer)
3.5.1.2 Eylea: The Next Blockbuster
3.5.1.3 Eylea Clinical Trials Data
3.5.1.4 Eylea Revenue Forecast, 2012-2022
3.5.2 Ophthalmic Revenue, 2011
3.5.3 FDA Approves Zaltrap (aflibercept)
3.5.4 Recent Licensing Deals
3.5.5 Eylea/Zaltrap and the Davis-Smyth VEGF-Trap Patents
3.5.6 Pipeline
3.5.7 Regeneron Ophthalmics: SWOT Analysis
3.5.8 Ophthalmic Revenue Forecast, 2012-2022
4. THE LEADING EUROPEAN OPHTHALMIC DRUG MANUFACTURERS 2012-2022
4.1 Novartis
4.1.1 Ophthalmic Product Portfolio
4.1.1.1 Lucentis
4.1.1.1.1 Lucentis Will Drive Novartis' Ophthalmic Segment
4.1.1.1.2 Lucentis Revenue Forecast, 2012-2022
4.1.1.2 Travatan Z
4.1.1.2.1 Travatan Z Revenue Forecast, 2012-2022
4.1.1.3 Vigamox/Vegamox (Moxifloxacin)
4.1.1.3.1 Vigamox Revenue Forecast, 2012-2022
4.1.1.4 Azopt
4.1.1.4.1 Azopt Revenue Forecast, 2012-2022
4.1.1.5 Extravan/Duotrav
4.1.1.5.1 Extravan/DuoTrav Revenue Forecast, 2012-2022
4.1.1.6 TobraDex
4.1.1.6.1 TobraDex Revenue Forecast, 2012-2022
4.1.2 Ophthalmic Revenue, 2011
4.1.3 Entering and Exiting Licensing Agreements
4.1.4 R&D Pipeline
4.1.4.1 Lucentis (Ranibizumab) for Pathological Myopia
4.1.4.2 Jetrea (ThromboGenics/Novartis)
4.1.4.3 TobraDex ST
4.1.4.4 Azarga
4.1.4.5 Anecortave
4.1.4.6 AL-37807
4.1.4.7 Durezol (Senju/Sirion Therapeutics/Alcon)
4.1.4.8 Moxifloxacin/Dexamethasone
4.1.4.9 Aganocide (Alcon/NovaBay)
4.1.4.10 Arxxant (Eli Lilly/Alcon/Takeda)
4.1.4.11 Finafloxacin
4.1.5 Novartis Ophthalmics: SWOT Analysis
4.1.6 Ophthalmic Revenue Forecast, 2012-2022
4.2 Roche (Genentech)
4.2.1 Roche
4.2.2 Ophthalmic Product Portfolio
4.2.2.1 Lucentis
4.2.2.2 Lucentis Will Drive Ophthalmic Sales
4.2.2.3 Lucentis Revenue Forecast, 2012-2022
4.2.2.4 Avastin Cannibalising Lucentis Revenues?
4.2.2.5 Avastin Revenue Forecast, 2012-2022
4.2.3 Ophthalmic Revenue, 2011
4.2.4 Roche Ophthalmics: SWOT Analysis
4.2.5 Ophthalmic Revenue Forecast, 2012-2022
5. THE LEADING JAPANESE OPHTHALMIC DRUG MANUFACTURERS 2012-2022
5.1 Santen Pharmaceutical
5.1.1 Ophthalmic Product Portfolio
5.1.1.1 Hyalein: Marketed in Japan and China
5.1.1.1.1 Hyalein Revenue Forecast, 2012-2022
5.1.1.2 Cravit/Quixin/Oftaquix (Levofloxacin)
5.1.1.2.1 Cravit/Quixin/Oftaquix Revenue Forecast, 2012-2022
5.1.2 Ophthalmic Revenue, 2011
5.1.3 Santen and Bayer to Co-promote Eylea in Japan
5.1.4 Santen Completes Acquisition of Novagali
5.1.5 Pipeline
5.1.5.1 Taflotan/DE-085 (Santen/Asahi)
5.1.5.2 Prolacria (Inspire/Allergan/Santen)
5.1.5.3 DE-089
5.1.5.4 DE-101/Rivoglitazone
5.1.5.5 DE-103
5.1.5.6 DE-110
5.1.6 Santen Ophthalmic: SWOT Analysis
5.1.7 Ophthalmic Revenue Forecast, 2012-2022
5.2 Senju Pharmaceutical
5.2.1 Ophthalmic Product Portfolio
5.2.2 Ophthalmic Revenue, 2011
5.2.3 Senju Launches Aiphgan for Glaucoma/Ocular Hypertension
5.2.4 Pipeline
5.2.4.1 Y-39983 (SNJ-1656)
5.2.4.2 Difluprednate (SJE-2079)
5.2.5 Senju Ophthalmic: SWOT Analysis
5.2.6 Ophthalmic Revenue Forecast, 2012-2022
6. EMERGING OPHTHALMIC MANUFACTURERS
6.1 Pipeline and Other Companies 2012
6.1.1 Other Big Pharma Players
6.1.2 Smaller Companies - Activities and Outlooks
6.1.2.1 BioDiem's BDM-E receives Orphan Drug Status
6.1.2.2 CoMentis Developing ATG003 (Topical Mecamylamine) for Wet AMD
6.1.2.3 Alimera Sciences' NADPH Inhibitors Offer Potential for Dry AMD
6.1.2.4 Gene Signal Leveraging its Gene Discovery Platform in AMD and DR Market
6.1.2.5 GenVec Developing AdPEDF for Wet AMD
6.1.2.6 ISTA Pharmaceuticals - Strong Presence in Prescription Eye Care
6.1.2.7 Shire's Acquisition of Jerini Boost its AMD Pipeline
6.1.2.8 KAI Pharmaceuticals Developing PKC Inhibitors for Ocular Market
6.1.2.9 Lpath's iSONEP Shows Early Promise
6.1.2.10 Neurotech's anti-VEGF Agents Show Early Promise
6.1.2.11 Ophthotech Corporation's Pipeline Offers Promise for Dry and Wet AMD
6.1.2.12 OPKO Health Developing siRNAs Technology
6.1.2.13 Othera Pharmaceuticals Exploring Potential Treatment for Geographic Atrophy in Dry AMD
6.1.2.14 Oxford BioMedica Developing Gene-Based Medicines for Eye Disease
6.1.2.15 Oxigene's Zybrestat, a Topical VDA agent in Phase II for Wet AMD
6.1.2.16 Potentia Developing Anti-inflammatory Ophthalmic Products
6.1.2.17 Sirion Therapeutics's Oral Medication Completes Phase II Trails for Patients with Geographic Atrophy
6.1.2.18 Sirnaomics Focusing on siRNA Technology
6.1.2.19 AmpliPhi Biosciences Corporation Leveraging its Bacteriphage Technology Platform for Ophthalmic Disease
6.1.2.20 ThromboGenics' Ocriplasmin in Development for AMD, DME and Symptomatic Vitreomacular Adhesion (SVMA)
7. CONCLUSIONS
7.1 Ophthalmic Pharmaceuticals: An Attractive Niche Market
7.2 Big Pharma Dominated the Ophthalmic Drug Market in 2011
7.3 The Rise of Generics
7.4 What Will Succeed in the Ophthalmic Pharmaceutical Market?
7.5 Small Companies Can Have a Big Impact on the Industry and Market to 2022
1.1 Leading Ophthalmic Drug Manufacturers: Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report
1.4.1 Drugs Considered for this Report
2. AN INTRODUCTION TO THE OPHTHALMIC DRUGS MARKET
2.1 The Ophthalmic Drug Market
2.1.1 The Ophthalmic Drugs Market in 2011
2.2 Ophthalmic Disorders
2.2.1 Glaucoma
2.2.1.1 Glaucoma Risk Factors
2.2.1.2 Diagnosis and Prevalence of Glaucoma
2.2.1.3 Treatment of Glaucoma
2.2.1.4 First-Line and Second-Line Treatment of Choice
2.2.1.5 Laser Treatment and Surgery (Trabeculectomy)
2.2.2 Age-Related Macular Degeneration (AMD)
2.2.2.1 AMD Risk Factors, Prevalence and Diagnosis
2.2.2.2 Treatment of AMD
2.2.3 Diabetic Retinopathy
2.2.3.1 Diagnosis and Prevalence of Diabetic Retinopathy
2.2.3.2 Laser and Surgical Treatments for Diabetic Retinopathy
2.2.3.3 Pharmaceutical Treatments
2.2.4 Ophthalmic Allergies: Allergic Conjunctivitis is the Most-Common Eye Allergy
2.2.4.1 Ophthalmic Allergy Treatments
2.2.5 Ophthalmic Inflammatory Disorders
2.2.5.1 Ophthalmic Inflammatory Drugs
2.2.6 Ophthalmic Infections
2.2.6.1 Treatment of Eye Infections
2.2.7 Dry Eye Syndrome
2.2.7.1 Causes and Prevalence of Dry Eye Syndrome
2.2.7.2 Treatments for Dry Eye Syndrome
2.3 The Ophthalmic Drugs Market: Overall Revenue Forecast 2012-2022
2.3.1 Market Drivers 2012-2022
2.3.2 Market Restraints 2012-2022
2.4 Leading Ophthalmic Drug Manufacturers in 2011
2.4.1 Company Comparison
2.4.2 Future of the Ophthalmic Drugs Industry
3. THE LEADING US OPHTHALMIC DRUG MANUFACTURERS 2012-2022
3.1 Allergan
3.1.1 Ophthalmic Product Portfolio
3.1.2 Allergan's Leading Product Forecast
3.1.2.1 Restasis - Allergan's Prescription Drug for Dry Eye
3.1.2.1.1 Restasis Revenue Forecast, 2012-2022
3.1.2.2 Lumigan Franchise
3.1.2.2.1 Lumigan Franchise Revenue Forecast, 2012-2022
3.1.2.3 Allergan's Refresh Brand, including Celluvisc, a Leading Brand in the Dry Eye Market
3.1.2.3.1 Refresh Brand including Celluvisc: Revenue Forecast, 2012-2022
3.1.2.4 Alphagan
3.1.2.4 1 Alphagan Revenue Forecast, 2012-2022
3.1.2.5 Combigan
3.1.2.5.1 Combigan Revenue Forecast, 2012-2022
3.1.2.6 Acular
3.1.2.6.1 Acular Revenue Forecast, 2012-2022
3.1.2.7 Allergan's Ozurdex, First Drug Therapy for Macular Oedema
3.1.3 Allergan's Ophthalmic Pipeline
3.1.3.1 Novadur/Sustained-Release Brimonidine (Allergan)
3.1.3.2 AGN-745/SIRNA-027 (Allergan/Merck & Co.)
3.1.3.3 DARPin/MP0112 (Allergan)
3.1.3.4 Prolacria (Inspire/Allergan/Santen)
3.1.4 Allergan's Other Specialty Areas
3.1.5 Allergan Manufacturing Capabilities
3.1.6 Allergan Ophthalmic Segment: SWOT Analysis
3.1.7 Allergan's Revenues
3.1.7.1 Ophthalmic Revenue Forecast, 2012-2022
3.2 Pfizer
3.2.1 Ophthalmic Product Portfolio
3.2.1.1 Macugen (pegaptanib)
3.2.1.2 Xalatan (latanoprost)
3.2.1.3 Xalacom (latanoprost/timolol)
3.2.1.4 Xalabrands (Xalatan/Xalacom) Revenue Forecast, 2012-2022
3.2.2 Ophthalmic Revenue, 2011
3.2.3 R&D Pipeline
3.2.3.1 Pipeline, 2007-2011
3.2.3.2 iSONEP
3.2.3.3 Tofacitinib (CP-690550)
3.2.3.4 RN6G (PF-04382923)
3.2.3.5 AtuRNAi (PF-04523655)
3.2.4 Pfizer Ophthalmics: SWOT Analysis
3.2.5 Ophthalmic Revenue Forecast, 2012-2022
3.3 Bausch + Lomb
3.3.1 A Long History in Ophthalmics
3.3.2 Key Eye Care Business Segments
3.3.3 Vision Care
3.3.4 Surgical
3.3.5 Pharmaceuticals
3.3.5.1 Lotemax
3.3.5.2 Lotemax Revenue Forecast, 2012-2022
3.3.6 Ophthalmic Revenue, 2011
3.3.7 Pipeline Products
3.3.8 Recent Mergers and Acquisitions
3.3.9 Bausch + Lomb Ophthalmics: SWOT Analysis
3.3.10 Ophthalmic Revenue Forecast, 2012-2022
3.4 Merck & Co.
3.4.1 Ophthalmic Product Portfolio
3.4.1.1 Trusopt
3.4.1.2 Cosopt
3.4.1.3 Trusopt Revenue Forecast, 2012-2022
3.4.1.4 Cosopt Revenue Forecast, 2012-2022
3.4.2 Ophthalmic Revenue, 2011
3.4.3 FDA Approves Zioptan (tafluprost)
3.4.4 Recent Merger and Acquisition Deals
3.4.5 Pipeline
3.4.5.1 Prolacria (Inspire/Allergan/Santen)
3.4.6 Merck Ophthalmics: SWOT Analysis
3.4.7 Ophthalmic Revenue Forecast, 2012-2022
3.5 Regeneron
3.5.1 Ophthalmic Product Portfolio
3.5.1.1 Eylea (Regeneron/Bayer)
3.5.1.2 Eylea: The Next Blockbuster
3.5.1.3 Eylea Clinical Trials Data
3.5.1.4 Eylea Revenue Forecast, 2012-2022
3.5.2 Ophthalmic Revenue, 2011
3.5.3 FDA Approves Zaltrap (aflibercept)
3.5.4 Recent Licensing Deals
3.5.5 Eylea/Zaltrap and the Davis-Smyth VEGF-Trap Patents
3.5.6 Pipeline
3.5.7 Regeneron Ophthalmics: SWOT Analysis
3.5.8 Ophthalmic Revenue Forecast, 2012-2022
4. THE LEADING EUROPEAN OPHTHALMIC DRUG MANUFACTURERS 2012-2022
4.1 Novartis
4.1.1 Ophthalmic Product Portfolio
4.1.1.1 Lucentis
4.1.1.1.1 Lucentis Will Drive Novartis' Ophthalmic Segment
4.1.1.1.2 Lucentis Revenue Forecast, 2012-2022
4.1.1.2 Travatan Z
4.1.1.2.1 Travatan Z Revenue Forecast, 2012-2022
4.1.1.3 Vigamox/Vegamox (Moxifloxacin)
4.1.1.3.1 Vigamox Revenue Forecast, 2012-2022
4.1.1.4 Azopt
4.1.1.4.1 Azopt Revenue Forecast, 2012-2022
4.1.1.5 Extravan/Duotrav
4.1.1.5.1 Extravan/DuoTrav Revenue Forecast, 2012-2022
4.1.1.6 TobraDex
4.1.1.6.1 TobraDex Revenue Forecast, 2012-2022
4.1.2 Ophthalmic Revenue, 2011
4.1.3 Entering and Exiting Licensing Agreements
4.1.4 R&D Pipeline
4.1.4.1 Lucentis (Ranibizumab) for Pathological Myopia
4.1.4.2 Jetrea (ThromboGenics/Novartis)
4.1.4.3 TobraDex ST
4.1.4.4 Azarga
4.1.4.5 Anecortave
4.1.4.6 AL-37807
4.1.4.7 Durezol (Senju/Sirion Therapeutics/Alcon)
4.1.4.8 Moxifloxacin/Dexamethasone
4.1.4.9 Aganocide (Alcon/NovaBay)
4.1.4.10 Arxxant (Eli Lilly/Alcon/Takeda)
4.1.4.11 Finafloxacin
4.1.5 Novartis Ophthalmics: SWOT Analysis
4.1.6 Ophthalmic Revenue Forecast, 2012-2022
4.2 Roche (Genentech)
4.2.1 Roche
4.2.2 Ophthalmic Product Portfolio
4.2.2.1 Lucentis
4.2.2.2 Lucentis Will Drive Ophthalmic Sales
4.2.2.3 Lucentis Revenue Forecast, 2012-2022
4.2.2.4 Avastin Cannibalising Lucentis Revenues?
4.2.2.5 Avastin Revenue Forecast, 2012-2022
4.2.3 Ophthalmic Revenue, 2011
4.2.4 Roche Ophthalmics: SWOT Analysis
4.2.5 Ophthalmic Revenue Forecast, 2012-2022
5. THE LEADING JAPANESE OPHTHALMIC DRUG MANUFACTURERS 2012-2022
5.1 Santen Pharmaceutical
5.1.1 Ophthalmic Product Portfolio
5.1.1.1 Hyalein: Marketed in Japan and China
5.1.1.1.1 Hyalein Revenue Forecast, 2012-2022
5.1.1.2 Cravit/Quixin/Oftaquix (Levofloxacin)
5.1.1.2.1 Cravit/Quixin/Oftaquix Revenue Forecast, 2012-2022
5.1.2 Ophthalmic Revenue, 2011
5.1.3 Santen and Bayer to Co-promote Eylea in Japan
5.1.4 Santen Completes Acquisition of Novagali
5.1.5 Pipeline
5.1.5.1 Taflotan/DE-085 (Santen/Asahi)
5.1.5.2 Prolacria (Inspire/Allergan/Santen)
5.1.5.3 DE-089
5.1.5.4 DE-101/Rivoglitazone
5.1.5.5 DE-103
5.1.5.6 DE-110
5.1.6 Santen Ophthalmic: SWOT Analysis
5.1.7 Ophthalmic Revenue Forecast, 2012-2022
5.2 Senju Pharmaceutical
5.2.1 Ophthalmic Product Portfolio
5.2.2 Ophthalmic Revenue, 2011
5.2.3 Senju Launches Aiphgan for Glaucoma/Ocular Hypertension
5.2.4 Pipeline
5.2.4.1 Y-39983 (SNJ-1656)
5.2.4.2 Difluprednate (SJE-2079)
5.2.5 Senju Ophthalmic: SWOT Analysis
5.2.6 Ophthalmic Revenue Forecast, 2012-2022
6. EMERGING OPHTHALMIC MANUFACTURERS
6.1 Pipeline and Other Companies 2012
6.1.1 Other Big Pharma Players
6.1.2 Smaller Companies - Activities and Outlooks
6.1.2.1 BioDiem's BDM-E receives Orphan Drug Status
6.1.2.2 CoMentis Developing ATG003 (Topical Mecamylamine) for Wet AMD
6.1.2.3 Alimera Sciences' NADPH Inhibitors Offer Potential for Dry AMD
6.1.2.4 Gene Signal Leveraging its Gene Discovery Platform in AMD and DR Market
6.1.2.5 GenVec Developing AdPEDF for Wet AMD
6.1.2.6 ISTA Pharmaceuticals - Strong Presence in Prescription Eye Care
6.1.2.7 Shire's Acquisition of Jerini Boost its AMD Pipeline
6.1.2.8 KAI Pharmaceuticals Developing PKC Inhibitors for Ocular Market
6.1.2.9 Lpath's iSONEP Shows Early Promise
6.1.2.10 Neurotech's anti-VEGF Agents Show Early Promise
6.1.2.11 Ophthotech Corporation's Pipeline Offers Promise for Dry and Wet AMD
6.1.2.12 OPKO Health Developing siRNAs Technology
6.1.2.13 Othera Pharmaceuticals Exploring Potential Treatment for Geographic Atrophy in Dry AMD
6.1.2.14 Oxford BioMedica Developing Gene-Based Medicines for Eye Disease
6.1.2.15 Oxigene's Zybrestat, a Topical VDA agent in Phase II for Wet AMD
6.1.2.16 Potentia Developing Anti-inflammatory Ophthalmic Products
6.1.2.17 Sirion Therapeutics's Oral Medication Completes Phase II Trails for Patients with Geographic Atrophy
6.1.2.18 Sirnaomics Focusing on siRNA Technology
6.1.2.19 AmpliPhi Biosciences Corporation Leveraging its Bacteriphage Technology Platform for Ophthalmic Disease
6.1.2.20 ThromboGenics' Ocriplasmin in Development for AMD, DME and Symptomatic Vitreomacular Adhesion (SVMA)
7. CONCLUSIONS
7.1 Ophthalmic Pharmaceuticals: An Attractive Niche Market
7.2 Big Pharma Dominated the Ophthalmic Drug Market in 2011
7.3 The Rise of Generics
7.4 What Will Succeed in the Ophthalmic Pharmaceutical Market?
7.5 Small Companies Can Have a Big Impact on the Industry and Market to 2022
LIST OF TABLES
Table 2.1 Ophthalmic Drugs Market: Revenue by Class, 2010-2011
Table 2.2 Glaucoma Drug Types, 2012
Table 2.3 AMD Drug Types, 2012
Table 2.4 Ophthalmic Allergy Drug Types, 2012
Table 2.5 Ophthalmic Inflammatory Disorder Drug Types, 2012
Table 2.6 Ophthalmic Anti-Infective Drug Types, 2012
Table 2.7 Ophthalmic Drugs: Overall World Market and Submarket Forecasting, 2011, 2016 & 2022
Table 2.8 Top 10 Ophthalmic Pharmaceutical Manufacturers: Revenue and Market Shares, 2011
Table 2.9 Leading Manufacturers: Ophthalmic Revenue as a Share of Pharmaceutical Revenue, 2011
Table 3.1 Allergan: Key Facts, 2012
Table 3.2 Allergan's Leading Brands: Revenue, 2011
Table 3.3 Allergan: Ophthalmic SWOT Analysis, 2012-2022
Table 3.4 Allergan: Ophthalmic Revenue Forecast, 2011-2022
Table 3.5 Pfizer: Key Facts, 2012
Table 3.6 Pfizer: Ophthalmic Revenue, 2009-2011
Table 3.7 Pfizer: Ophthalmic SWOT Analysis, 2012-2022
Table 3.8 Pfizer: Ophthalmic Revenue Forecast, 2011-2022
Table 3.9 Bausch + Lomb: Key Facts, 2012
Table 3.10 Bausch + Lomb: Ophthalmic Revenue, 2009-2011
Table 3.11 Bausch + Lomb: Ophthalmic SWOT Analysis, 2012-2022
Table 3.12 Bausch + Lomb: Ophthalmic Revenue Forecast, 2011-2022
Table 3.13 Merck & Co: Key Facts, 2012
Table 3.14 Merck & Co: Ophthalmic Revenue, 2009-2011
Table 3.15 Merck & Co: Ophthalmic SWOT Analysis, 2012-2022
Table 3.16 Merck & Co: Ophthalmic Revenue Forecast, 2011-2022
Table 3.17 Regeneron: Key Facts, 2012
Table 3.18 Regeneron: Ophthalmic Revenue, Q4 2011-Q2 2012
Table 3.19 Regeneron: Ophthalmic SWOT Analysis, 2012-2022
Table 3.20 Regeneron: Ophthalmic Revenue Forecast, 2011-2022
Table 4.1 Novartis: Key Facts, 2012
Table 4.2 Novartis: Ophthalmic Revenue, 2010-2011
Table 4.3 Novartis: Ophthalmic SWOT Analysis, 2012-2022
Table 4.4 Novartis: Ophthalmic Revenue Forecast, 2011-2022
Table 4.5 Roche: Key Facts, 2012
Table 4.6 Roche: Ophthalmic SWOT Analysis, 2012-2022
Table 4.7 Roche: Ophthalmic Revenue Forecast, 2011-2022
Table 5.1 Santen: Key Facts, 2012
Table 5.2 Santen: Ophthalmic Revenue, FY 2007-2011
Table 5.3 Santen: Ophthalmic SWOT Analysis, 2012-2022
Table 5.4 Santen: Ophthalmic Revenue Forecast, 2011-2022
Table 5.5 Senju: Key Facts, 2012
Table 5.6 Senju: Ophthalmic Revenue, FY 2007-2011
Table 5.7 Senju: Ophthalmic SWOT Analysis, 2012-2022
Table 5.8 Senju: Ophthalmic Revenue Forecast, 2011-2022
Table 7.1 Leading Ophthalmic Manufacturers by Company Type, 2011
Table 2.1 Ophthalmic Drugs Market: Revenue by Class, 2010-2011
Table 2.2 Glaucoma Drug Types, 2012
Table 2.3 AMD Drug Types, 2012
Table 2.4 Ophthalmic Allergy Drug Types, 2012
Table 2.5 Ophthalmic Inflammatory Disorder Drug Types, 2012
Table 2.6 Ophthalmic Anti-Infective Drug Types, 2012
Table 2.7 Ophthalmic Drugs: Overall World Market and Submarket Forecasting, 2011, 2016 & 2022
Table 2.8 Top 10 Ophthalmic Pharmaceutical Manufacturers: Revenue and Market Shares, 2011
Table 2.9 Leading Manufacturers: Ophthalmic Revenue as a Share of Pharmaceutical Revenue, 2011
Table 3.1 Allergan: Key Facts, 2012
Table 3.2 Allergan's Leading Brands: Revenue, 2011
Table 3.3 Allergan: Ophthalmic SWOT Analysis, 2012-2022
Table 3.4 Allergan: Ophthalmic Revenue Forecast, 2011-2022
Table 3.5 Pfizer: Key Facts, 2012
Table 3.6 Pfizer: Ophthalmic Revenue, 2009-2011
Table 3.7 Pfizer: Ophthalmic SWOT Analysis, 2012-2022
Table 3.8 Pfizer: Ophthalmic Revenue Forecast, 2011-2022
Table 3.9 Bausch + Lomb: Key Facts, 2012
Table 3.10 Bausch + Lomb: Ophthalmic Revenue, 2009-2011
Table 3.11 Bausch + Lomb: Ophthalmic SWOT Analysis, 2012-2022
Table 3.12 Bausch + Lomb: Ophthalmic Revenue Forecast, 2011-2022
Table 3.13 Merck & Co: Key Facts, 2012
Table 3.14 Merck & Co: Ophthalmic Revenue, 2009-2011
Table 3.15 Merck & Co: Ophthalmic SWOT Analysis, 2012-2022
Table 3.16 Merck & Co: Ophthalmic Revenue Forecast, 2011-2022
Table 3.17 Regeneron: Key Facts, 2012
Table 3.18 Regeneron: Ophthalmic Revenue, Q4 2011-Q2 2012
Table 3.19 Regeneron: Ophthalmic SWOT Analysis, 2012-2022
Table 3.20 Regeneron: Ophthalmic Revenue Forecast, 2011-2022
Table 4.1 Novartis: Key Facts, 2012
Table 4.2 Novartis: Ophthalmic Revenue, 2010-2011
Table 4.3 Novartis: Ophthalmic SWOT Analysis, 2012-2022
Table 4.4 Novartis: Ophthalmic Revenue Forecast, 2011-2022
Table 4.5 Roche: Key Facts, 2012
Table 4.6 Roche: Ophthalmic SWOT Analysis, 2012-2022
Table 4.7 Roche: Ophthalmic Revenue Forecast, 2011-2022
Table 5.1 Santen: Key Facts, 2012
Table 5.2 Santen: Ophthalmic Revenue, FY 2007-2011
Table 5.3 Santen: Ophthalmic SWOT Analysis, 2012-2022
Table 5.4 Santen: Ophthalmic Revenue Forecast, 2011-2022
Table 5.5 Senju: Key Facts, 2012
Table 5.6 Senju: Ophthalmic Revenue, FY 2007-2011
Table 5.7 Senju: Ophthalmic SWOT Analysis, 2012-2022
Table 5.8 Senju: Ophthalmic Revenue Forecast, 2011-2022
Table 7.1 Leading Ophthalmic Manufacturers by Company Type, 2011
LIST OF FIGURES
Figure 2.1 Ophthalmic Drugs Market: Revenue by Class, 2010-2011
Figure 2.2 Ophthalmic Drugs: Overall Market Forecast, 2011, 2016 & 2022
Figure 2.3 Ophthalmic Drugs Market: Drivers and Restraints, 2012-2022
Figure 2.4 Top 10 Ophthalmic Pharmaceutical Manufacturers: Market Shares, 2011
Figure 3.1 Restasis Revenue Forecast, 2011-2016
Figure 3.2 Restasis Revenue Forecast, 2017-2022
Figure 3.3 Lumigan Franchise Revenue Forecast, 2011-2016
Figure 3.4 Lumigan Franchise Revenue Forecast, 2017-2022
Figure 3.5 Refresh Brand including Celluvisc Revenue Forecast, 2011-2016
Figure 3.6 Refresh Brand including Celluvisc Revenue Forecast, 2017-2022
Figure 3.7 Alphagan Revenue Forecast, 2011-2016
Figure 3.8 Alphagan Revenue Forecast, 2017-2022
Figure 3.9 Combigan Revenue Forecast, 2011-2016
Figure 3.10 Combigan Revenue Forecast, 2017-2022
Figure 3.11 Acular Revenue Forecast, 2011-2016
Figure 3.12 Acular Revenue Forecast, 2017-2022
Figure 3.13 Allergan: Ophthalmic Revenue Forecast, 2011-2022
Figure 3.14 Allergan: Ophthalmic Market Share, 2011-2022
Figure 3.15 Xalabrands (Xalatan/Xalacom) Revenue Forecast, 2011-2016
Figure 3.16 Xalabrands (Xalatan/Xalacom) Revenue Forecast, 2017-2022
Figure 3.17 Pfizer: Ophthalmic Revenue Forecast, 2011-2022
Figure 3.18 Pfizer: Ophthalmic Market Share, 2011-2022
Figure 3.19 Lotemax Revenue Forecast, 2011-2016
Figure 3.20 Lotemax Revenue Forecast, 2017-2022
Figure 3.21 Bausch + Lomb Ophthalmic Revenue Forecast, 2011-2022
Figure 3.22 Bausch + Lomb: Ophthalmic Market Share, 2011-2022
Figure 3.23 Trusopt Revenue Forecast, 2011-2016
Figure 3.24 Trusopt Revenue Forecast, 2017-2022
Figure 3.25 Cosopt Revenue Forecast, 2011-2016
Figure 3.26 Cosopt Revenue Forecast, 2017-2022
Figure 3.27 Merck & Co: Ophthalmic Revenue, 2009-2011
Figure 3.28 Merck & Co: Ophthalmic Revenue Forecast, 2011-2022
Figure 3.29 Merck & Co: Ophthalmic Market Share, 2011-2022
Figure 3.30 Eylea Revenue Forecast, 2011-2016
Figure 3.31 Eylea Revenue Forecast, 2017-2022
Figure 3.32 Regeneron: Ophthalmic Revenue, Q4 2011-Q2 2012
Figure 3.33 Regeneron: Ophthalmic Revenue Forecast, 2011-2022
Figure 3.34 Regeneron: Ophthalmic Market Share, 2011-2022
Figure 4.1 Lucentis: Novartis Revenue Breakdown, 2008-2011
Figure 4.2 Lucentis Revenue (ROW) Forecast, 2011-2016
Figure 4.3 Lucentis Revenue (ROW) Forecast, 2017-2022
Figure 4.4 Travatan Z Revenue Forecast, 2011-2016
Figure 4.5 Travatan Z Revenue Forecast, 2017-2022
Figure 4.6 Vigamox Revenue Forecast, 2011-2016
Figure 4.7 Vigamox Revenue Forecast, 2017-2022
Figure 4.8 Azopt Revenue Forecast, 2011-2016
Figure 4.9 Azopt Revenue Forecast, 2017-2022
Figure 4.10 Extravan/DuoTrav Revenue Forecast, 2011-2016
Figure 4.11 Extravan/DuoTrav Revenue Forecast, 2017-2022
Figure 4.12 TobraDex Revenue Forecast, 2011-2016
Figure 4.13 TobraDex Revenue Forecast, 2017-2022
Figure 4.14 Novartis: Ophthalmic Revenue Shares, 2011
Figure 4.15 Novartis: Ophthalmic Revenue Forecast, 2011-2022
Figure 4.16 Novartis: Ophthalmic Market Share, 2011-2022
Figure 4.17 Lucentis Revenue (US) Forecast, 2011-2016
Figure 4.18 Lucentis Revenue (US) Forecast, 2017-2022
Figure 4.19 Avastin Revenue Forecast, 2011-2016
Figure 4.20 Avastin Revenue Forecast, 2017-2022
Figure 4.21 Lucentis: Roche's Revenue Breakdown, 2008-2011
Figure 4.22 Roche: Ophthalmic Revenue Forecast, 2011-2022
Figure 4.23 Roche: Ophthalmic Market Share, 2011-2022
Figure 5.1 Santen Revenue by Segment, 2011
Figure 5.2 Hyalein Revenue Forecast, 2011-2016
Figure 5.3 Hyalein Revenue Forecast, 2017-2022
Figure 5.4 Cravit/Quixin/Oftaquix Revenue Forecast, 2011-2016
Figure 5.5 Cravit/Quixin/Oftaquix Revenue Forecast, 2017-2022
Figure 5.6 Santen: Ophthalmic Revenue, FY 2007-2011
Figure 5.7 Santen: Ophthalmic Revenue Forecast, 2011-2022
Figure 5.8 Santen: Ophthalmic Market Share, 2011-2022
Figure 5.9 Senju: Ophthalmic Revenue, FY 2007-2011
Figure 5.10 Senju: Ophthalmic Revenue Forecast, 2011-2022
Figure 5.11 Senju: Ophthalmic Market Share, 2011-2022
Figure 7.1 Ophthalmic Pharmaceutical Market: Overall World Revenue, 2011-2022
Figure 7.2 Leading Ophthalmic Manufacturers: Revenue Forecasts, 2011-2022
COMPANIES LISTED
Alcon Laboratories
Alimera Sciences
Allergan
Allergan Pharmaceuticals Ireland
American Academy of Ophthalmology (AAO)
American Diabetes Association
American Society of Retina Specialists (ASRS)
AmpliPhi BioSciences Corporation
Asahi
Astellas Pharma
AstraZeneca
Banyu Pharmaceutical Co (currently MSD K.K.)
Bausch + Lomb (B&L)
Bayer
Bayer HealthCare
Bayer Yakuhin (Bayer's Japanese subsidiary)
Bristol-Myers Squibb
BioDiem
BioInvent International
Cambridge University
Centre for Molecular and Vascular Biology, KU Leuven.
Chugai
CIBA Vision
Ciba-Geigy
Clinical Data
CoMentis
CT Freda
Daiichi Sankyo
EAME countries
Eli Lilly
Esteve
European Medicines Agency (EMEA/EMA)
EyeTech Pharmaceuticals (now OSI Pharmaceuticals)
Food and Drug Administration (FDA) [US]
Forest Laboratories
Gene Signal
Genentech
GenVec
Gilead Sciences,
GlaxoSmithKline (GSK)
Harvard Business School
Hoffman La Roche
Inspire Pharmaceuticals
ISTA Pharmaceuticals
Johns Hopkins University
KAI Pharmaceuticals
Kyorin Pharmaceutical
Kyowa Hakko Kirin
LEO Pharma
Lpath
MacuSight
Meda
Merck & Co.
Merial
MerLion Pharmaceuticals
Ministry for Health, Labor and Welfare [Japan]
Molecular Partners
Monash University
MSD K.K
Mylan Seiyaku
National Eye Institute (NEI)
National Health Service (NHS)
National Institute for Health and Clinical Excellence (NICE)
Neurotech
Nichi-Iko Pharmaceutical
Nipro Pharma
Nobilon International
NovaBay Pharmaceuticals
Novagali Pharma
Novartis
Novartis Institutes for BioMedical Research (NIBR)
Oklahoma Medical Research Foundation
Ophthotech
OPKO Health
OSI Pharmaceuticals
Othera Pharmaceuticals
Oxford BioMedica
Oxigene
Pfizer
Pharmacia
Potentia
pSivida
Purdue University
QLT
Quark
Regeneron
ReVision Therapeutics
Roche
Sandoz
Sanofi
Santen Pharmaceutical Co.
Senju Pharmaceuticals Science & Technology (Beijing) Co.
Senju Pharmaceutical
Senju USA
Shandong University
Shire
Sirion Therapeutics
Sirnaomics
Sun Pharmaceutical Industries
Taiyo Yakuhin
Takeda
TargeGen
Teva Pharmaceutical Industries
Therapeutic Goods Administration (TGA)
ThromboGenics
University College London
University of Melbourne
Upjohn
Warburg Pincus
Warner-Lambert
Watson Pharmaceuticals
Wyeth Pharmaceuticals
Figure 2.1 Ophthalmic Drugs Market: Revenue by Class, 2010-2011
Figure 2.2 Ophthalmic Drugs: Overall Market Forecast, 2011, 2016 & 2022
Figure 2.3 Ophthalmic Drugs Market: Drivers and Restraints, 2012-2022
Figure 2.4 Top 10 Ophthalmic Pharmaceutical Manufacturers: Market Shares, 2011
Figure 3.1 Restasis Revenue Forecast, 2011-2016
Figure 3.2 Restasis Revenue Forecast, 2017-2022
Figure 3.3 Lumigan Franchise Revenue Forecast, 2011-2016
Figure 3.4 Lumigan Franchise Revenue Forecast, 2017-2022
Figure 3.5 Refresh Brand including Celluvisc Revenue Forecast, 2011-2016
Figure 3.6 Refresh Brand including Celluvisc Revenue Forecast, 2017-2022
Figure 3.7 Alphagan Revenue Forecast, 2011-2016
Figure 3.8 Alphagan Revenue Forecast, 2017-2022
Figure 3.9 Combigan Revenue Forecast, 2011-2016
Figure 3.10 Combigan Revenue Forecast, 2017-2022
Figure 3.11 Acular Revenue Forecast, 2011-2016
Figure 3.12 Acular Revenue Forecast, 2017-2022
Figure 3.13 Allergan: Ophthalmic Revenue Forecast, 2011-2022
Figure 3.14 Allergan: Ophthalmic Market Share, 2011-2022
Figure 3.15 Xalabrands (Xalatan/Xalacom) Revenue Forecast, 2011-2016
Figure 3.16 Xalabrands (Xalatan/Xalacom) Revenue Forecast, 2017-2022
Figure 3.17 Pfizer: Ophthalmic Revenue Forecast, 2011-2022
Figure 3.18 Pfizer: Ophthalmic Market Share, 2011-2022
Figure 3.19 Lotemax Revenue Forecast, 2011-2016
Figure 3.20 Lotemax Revenue Forecast, 2017-2022
Figure 3.21 Bausch + Lomb Ophthalmic Revenue Forecast, 2011-2022
Figure 3.22 Bausch + Lomb: Ophthalmic Market Share, 2011-2022
Figure 3.23 Trusopt Revenue Forecast, 2011-2016
Figure 3.24 Trusopt Revenue Forecast, 2017-2022
Figure 3.25 Cosopt Revenue Forecast, 2011-2016
Figure 3.26 Cosopt Revenue Forecast, 2017-2022
Figure 3.27 Merck & Co: Ophthalmic Revenue, 2009-2011
Figure 3.28 Merck & Co: Ophthalmic Revenue Forecast, 2011-2022
Figure 3.29 Merck & Co: Ophthalmic Market Share, 2011-2022
Figure 3.30 Eylea Revenue Forecast, 2011-2016
Figure 3.31 Eylea Revenue Forecast, 2017-2022
Figure 3.32 Regeneron: Ophthalmic Revenue, Q4 2011-Q2 2012
Figure 3.33 Regeneron: Ophthalmic Revenue Forecast, 2011-2022
Figure 3.34 Regeneron: Ophthalmic Market Share, 2011-2022
Figure 4.1 Lucentis: Novartis Revenue Breakdown, 2008-2011
Figure 4.2 Lucentis Revenue (ROW) Forecast, 2011-2016
Figure 4.3 Lucentis Revenue (ROW) Forecast, 2017-2022
Figure 4.4 Travatan Z Revenue Forecast, 2011-2016
Figure 4.5 Travatan Z Revenue Forecast, 2017-2022
Figure 4.6 Vigamox Revenue Forecast, 2011-2016
Figure 4.7 Vigamox Revenue Forecast, 2017-2022
Figure 4.8 Azopt Revenue Forecast, 2011-2016
Figure 4.9 Azopt Revenue Forecast, 2017-2022
Figure 4.10 Extravan/DuoTrav Revenue Forecast, 2011-2016
Figure 4.11 Extravan/DuoTrav Revenue Forecast, 2017-2022
Figure 4.12 TobraDex Revenue Forecast, 2011-2016
Figure 4.13 TobraDex Revenue Forecast, 2017-2022
Figure 4.14 Novartis: Ophthalmic Revenue Shares, 2011
Figure 4.15 Novartis: Ophthalmic Revenue Forecast, 2011-2022
Figure 4.16 Novartis: Ophthalmic Market Share, 2011-2022
Figure 4.17 Lucentis Revenue (US) Forecast, 2011-2016
Figure 4.18 Lucentis Revenue (US) Forecast, 2017-2022
Figure 4.19 Avastin Revenue Forecast, 2011-2016
Figure 4.20 Avastin Revenue Forecast, 2017-2022
Figure 4.21 Lucentis: Roche's Revenue Breakdown, 2008-2011
Figure 4.22 Roche: Ophthalmic Revenue Forecast, 2011-2022
Figure 4.23 Roche: Ophthalmic Market Share, 2011-2022
Figure 5.1 Santen Revenue by Segment, 2011
Figure 5.2 Hyalein Revenue Forecast, 2011-2016
Figure 5.3 Hyalein Revenue Forecast, 2017-2022
Figure 5.4 Cravit/Quixin/Oftaquix Revenue Forecast, 2011-2016
Figure 5.5 Cravit/Quixin/Oftaquix Revenue Forecast, 2017-2022
Figure 5.6 Santen: Ophthalmic Revenue, FY 2007-2011
Figure 5.7 Santen: Ophthalmic Revenue Forecast, 2011-2022
Figure 5.8 Santen: Ophthalmic Market Share, 2011-2022
Figure 5.9 Senju: Ophthalmic Revenue, FY 2007-2011
Figure 5.10 Senju: Ophthalmic Revenue Forecast, 2011-2022
Figure 5.11 Senju: Ophthalmic Market Share, 2011-2022
Figure 7.1 Ophthalmic Pharmaceutical Market: Overall World Revenue, 2011-2022
Figure 7.2 Leading Ophthalmic Manufacturers: Revenue Forecasts, 2011-2022
COMPANIES LISTED
Alcon Laboratories
Alimera Sciences
Allergan
Allergan Pharmaceuticals Ireland
American Academy of Ophthalmology (AAO)
American Diabetes Association
American Society of Retina Specialists (ASRS)
AmpliPhi BioSciences Corporation
Asahi
Astellas Pharma
AstraZeneca
Banyu Pharmaceutical Co (currently MSD K.K.)
Bausch + Lomb (B&L)
Bayer
Bayer HealthCare
Bayer Yakuhin (Bayer's Japanese subsidiary)
Bristol-Myers Squibb
BioDiem
BioInvent International
Cambridge University
Centre for Molecular and Vascular Biology, KU Leuven.
Chugai
CIBA Vision
Ciba-Geigy
Clinical Data
CoMentis
CT Freda
Daiichi Sankyo
EAME countries
Eli Lilly
Esteve
European Medicines Agency (EMEA/EMA)
EyeTech Pharmaceuticals (now OSI Pharmaceuticals)
Food and Drug Administration (FDA) [US]
Forest Laboratories
Gene Signal
Genentech
GenVec
Gilead Sciences,
GlaxoSmithKline (GSK)
Harvard Business School
Hoffman La Roche
Inspire Pharmaceuticals
ISTA Pharmaceuticals
Johns Hopkins University
KAI Pharmaceuticals
Kyorin Pharmaceutical
Kyowa Hakko Kirin
LEO Pharma
Lpath
MacuSight
Meda
Merck & Co.
Merial
MerLion Pharmaceuticals
Ministry for Health, Labor and Welfare [Japan]
Molecular Partners
Monash University
MSD K.K
Mylan Seiyaku
National Eye Institute (NEI)
National Health Service (NHS)
National Institute for Health and Clinical Excellence (NICE)
Neurotech
Nichi-Iko Pharmaceutical
Nipro Pharma
Nobilon International
NovaBay Pharmaceuticals
Novagali Pharma
Novartis
Novartis Institutes for BioMedical Research (NIBR)
Oklahoma Medical Research Foundation
Ophthotech
OPKO Health
OSI Pharmaceuticals
Othera Pharmaceuticals
Oxford BioMedica
Oxigene
Pfizer
Pharmacia
Potentia
pSivida
Purdue University
QLT
Quark
Regeneron
ReVision Therapeutics
Roche
Sandoz
Sanofi
Santen Pharmaceutical Co.
Senju Pharmaceuticals Science & Technology (Beijing) Co.
Senju Pharmaceutical
Senju USA
Shandong University
Shire
Sirion Therapeutics
Sirnaomics
Sun Pharmaceutical Industries
Taiyo Yakuhin
Takeda
TargeGen
Teva Pharmaceutical Industries
Therapeutic Goods Administration (TGA)
ThromboGenics
University College London
University of Melbourne
Upjohn
Warburg Pincus
Warner-Lambert
Watson Pharmaceuticals
Wyeth Pharmaceuticals
